Drugs / Lactobacillus rhamnosus
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06793514 | Feb → May 2025 overdue | dry eye syndrome | Mohsen Pourazizi | Not yet recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07709533 | Jul 2026 → Jun 2029 expected | — | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06560879 | Feb → Dec 2025 overdue | digestive system disorder, precursor lymphoblastic lymphoma/leukemia | National Institute of Pediatrics, Mexico | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT02711800 | Nov 2016 → Sep 2017 | anxiety | Nancy Zucker | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01436448 | Oct 2011 → Nov 2012 | glucose intolerance | Aga Khan University | Unknown | No outcome recorded |
| Phase not applicable5 trials · 1 missed | ||||||
| — | NCT04639141 | Dec 2021 → Apr 2022 | anxiety, autism spectrum disorder | The University of Queensland | Completed | No outcome recorded |
| — | NCT04706559 | Jan → Sep 2021 | atopic eczema | B.P. Koirala Institute of Health Sciences | Completed | No outcome recorded |
| — | NCT03527680 | Sep → Nov 2016 | — | nooshin dalili | Completed | No outcome recorded |
| — | NCT02764684 | Jan 2015 → Jul 2016 | HIV infectious disease | Rigshospitalet, Denmark | Completed | No outcome recorded |
| — | NCT00224432 | Mar 2001 → Sep 2002 | atopic eczema | Groningen Research Institute for Asthma and COPD | Completed | Missed primary |
| Comparator or background therapy2 trials | ||||||
| — | NCT06872320 Comparator | Mar 2025 → Dec 2026 expected | congenital heart disease, immune dysregulation, neurodevelopmental defects, and colitis, protein-energy malnutrition | Chang Gung Memorial Hospital | Active not recruiting | No outcome recorded |
| — | NCT02693041 Comparator | Jun 2012 → Sep 2021 | preeclampsia | Sahlgrenska University Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus rhamnosus | “The experimental group will receive the oral probiotics (Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium...” NCT06793514 ↗12“The probiotic strain Lactobacillus rhamnosus will be self-administrated twice a day, one capsule in the morning and one in the evening for eight weeks.” NCT02764684 ↗ “Active ingredient containing Lactobacillus rhamnosus (LGG)” NCT02693041 ↗ “The combination includes: Lactobacillus rhamnosus” NCT04639141 ↗ “Dietary Supplement: Lactobacillus rhamnosus” NCT03527680 ↗ “Lactobacillus rhamnosus” NCT02764684 ↗ |
| Known as | MoProbi-LR Capsules | “Lactobacillus Rhamnosus (Lactobacillus Rhamnosus, MoProbi-LR Capsules, Drug permit license 052531)” NCT06872320 ↗ |
| Modality | Other / unclassified | “two probiotic strains of bacteria” PMID 16839405 ↗ Jul 2006 |
| Route | Oral | “oral supplementation with these probiotic bacterial strains” PMID 16839405 ↗ Jul 2006 |